Herbalife Lowers Sales Growth Guidance On Eve Of Promoting Growth Drivers At Investor Day
Executive Summary
Lowers Q3 net sales guidance to a decrease of 3.5% to 6.5% after previously forecasting a range between 5% growth and 1% decrease; for the year, it lowers previous estimate of 8.5% to 12.5% growth to net sales improving 4.5% to 8.5%.
You may also be interested in...
US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan
July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.
Herbalife’s China Growth Plan Includes Expediting Business Licensing, Tighter Hiring Standards
Four-point China initiative also includes implementing sales strategy already a fixture in other regions, nutrition clubs with daily meetings. China's April-June results compelled firm to lower earnings forecast.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.